Nat. Rev. Neurol. doi: /nrneurol

Slides:

Advertisements

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Advertisements

From: High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study Ann Intern Med. 2004;140(2):85-93.

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Progression-free survival, according to treatment group

Figure 3 Life expectancy at birth in all countries included

MRI and possible differentiating features with nonconventional MRI

Figure 1 Perivenous distribution of multiple sclerosis lesions

Figure 4 Paradoxical immune reconstitution inflammatory syndrome

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Systemic immune responses to cryptococcal antigen

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

Figure 1 The topographical model of multiple sclerosis, clinical (A) and subclinical (B) views The topographical model of multiple sclerosis, clinical.

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 7 The efficacy of phosphate-binder therapy

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Proportion of patients for whom NEDA

Figure 5 Number of AHSCT procedures for

Figure 4 Neuromyelitis optica spectrum disorder brain lesions

Figure 1 Outline of the AHSCT procedure

Figure 5 Corticosteroid treatment can reduce brain

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 2 Proposed model of therapeutic mechanisms of AHSCT

Figure 1 Allele frequency and effect size for ALS-associated genes

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Hypothetical mechanisms of smoking-associated

Figure 2 Poststroke plasticity and recovery

Nat. Rev. Urol. doi: /nrurol

Figure 2 Algorithm for immunosuppressive treatment

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Principles of therapeutic ultrasound

Figure 5 Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients.

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 4 Flow chart of the MDS MSA Study Group aims

Figure 3 Genetic pleiotropy in ALS

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Lifestyle and environmental factors affect

Figure 1 Evolution of multiple sclerosis

Figure 1 The trajectory of cognitive ageing

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Anatomical patterns of neuropathy

Figure 1 Proportional motor recovery in the upper limb

Figure 3 Stroke-related deaths and DALYs by country development status

Figure 2 Age-specific prevalence of common comorbidities

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

Figure 6 Combining population-wide and high-risk strategies

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Logistical requirements for autologous

Figure 3 Potential interplay between physiological

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 The VEGF family of growth factors

Figure 2 Cellular pathways implicated in CIPN

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 3 Overall survival, according to treatment group

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Timing of the effects of deep brain stimulation

Figure 1 A large number of genes are potentially associated with CIPN

Nat. Rev. Neurol. doi: /nrneurol

Figure 5 Increased B cell-activating factor (BAFF) levels are shared between immunomodulatory treatments Increased B cell-activating factor (BAFF) levels.

Figure 3 Rett syndrome severity and age at diagnosis by mutation type

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 JCV serostatus JCV serostatus (A) Serostatus of 1,921 natalizumab-treated patients with multiple sclerosis, with JCV− patients shown in black.

Figure 5 Pairwise correlations between selected patient-reported outcomes and performance tests in patients with MS (A) The number of pairwise correlations.

Figure 3 Craniospinal irradiation proton therapy for medulloblastoma

Figure 3 Multiple sclerosis (MS) immunomodulatory treatments interferon-β (IFNB) and fingolimod (FTY720) result in global perturbation of the immune system.

Figure Avidity of IgG specific for influenza A and B following flu vaccinationAvidity of immunoglobulin (Ig) G specific for influenza A and B before and.

Keratinocyte growth factor (KGF) versus no KGF for the reduction of severe oral mucositis in patients receiving treatment for cancer or undergoing haematopoietic.

Cryotherapy versus no cryotherapy for the reduction of severe oral mucositis in patients receiving treatment for cancer or undergoing haematopoietic stem.

Presentation transcript:

Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.81 Figure 4 Estimated lymphoablative and myeloablative effects of AHSCT protocols for multiple sclerosis Figure 4 | Estimated lymphoablative and myeloablative effects of AHSCT protocols for multiple sclerosis. The expected relative lymphoablative and myeloablative effects in different conditioning protocols used in autologous haematopoietic stem cell transplantation (AHSCT) are depicted. Quantitative metrics are unavailable, and the size of the circles indicates the error in the estimates and the variability of the effects attainable in different patients. The dotted line represents the threshold of the myeloablative effect, above which haematopoietic stem cell (HSC) support is required for haematopoietic recovery and patient survival; in most patients treated with protocols below this threshold, haematopoiesis can recover without HSC transplantation, albeit with a longer recovery interval. These protocols are, therefore, considered non-myeloablative68. Muraro, P. A. et al. (2017) Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.81